Table 1

Methodological quality assessment items15

AKey baseline characteristics are presented separately for treatment groups (age, and at least one outcome measure) and for cluster randomised controlled trials and controlled trials, positive if baseline outcomes were statistically tested and results of tests were provided
BRandomisation procedure clearly and explicitly described and adequately carried out (generation of allocation sequence, allocation concealment and implementation)
CValidated measures of motor development used (validation in same age group reported and/or cited)
DDrop out described and ≤20% for <6-month follow-up or ≤30% for ≥6-month follow-up
EBlinded outcome assessments (positive when those responsible for assessing motor development at outcome were blinded to group allocation of individual participants)
FMotor development assessed a minimum of 6 months after pretest
GIntention to treat analysis for motor development outcomes(s) (participants analysed in group they were originally allocated to, and participants not excluded from analyses because of non-compliance to treatment or because of some missing data)
HPotential confounders accounted for in motor development analysis (eg, baseline score, group/cluster, age)
ISummary results for each group+treatment effect (difference between groups)+its precision (eg, 95% CI)
JPower calculation reported, and the study was adequately powered to detect hypothesised relationships